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Introduction
Myocardial infarction is the leading cause of sudden death and 
long term disability. Unfortunately it is also one of the most common 
perioperative complication associated with surgery and is particularly 
prevalent in patients with diabetes [1]. Reperfusion therapies such as 
thrombolysis and percutaneous coronary intervention are the mainstay 
of current treatment to restore coronary blood flow in order to salvage 
the ischemic heart, but paradoxically, reperfusion may itself cause 
lethal tissue injury, termed “ischemia-reperfusion injury (IRI)” [2].
Ischemic preconditioning (IPC) achieved by brief episodes of 
ischemia and reperfusion, given before prolonged ischemia, provide 
profound protection and has been considered as a powerful maneuver 
against myocardial ischemic injury in vivo [3,4]. Although effective, 
IPC requires access to the coronary vessels which is not feasible in 
the majority of cases. Recently, attention has focused on modifying 
events occurring at the time of myocardial reperfusion (i.e., ischemic 
postconditioning, IPostC). This phenomenon, in which the application 
of transient brief interruptions of reperfusion by ischemic episodes 
results in reduced myocardial injury, has led to renewed interest in 
the development of protective maneuvers to combat lethal reperfusion 
injury [5]. Currently, we and others have found that anesthetic 
drugs such as isoflurane [6,7], sevoflurane [8] and morphine [9] 
have similar infarction limitation properties to those of IPC and 
IPostC, this maneuver is termed pharmacological or anesthetic pre/
postconditioning (APC). In addition, antioxidant intervention with 
respect to reduce oxidative stress and normalize myocardial antioxidant 
defense, has also been proven to be a cardioprotective way against IRI, 
which has been demonstrated by Wang et al. and Nie et al. [10,11] 
and others. Unfortunately, all these effects of current available means 
of cardioprotection (IPC, IPostC, APC and antioxidant intervention) 
are abolished or compromised under pathological conditions such as 
diabetes [12] and yet diabetics are particularly prone to myocardial IRI 
[13]. 
Numerous studies have indicated that the diabetic heart is more 
sensitive to ischemia/reperfusion injury (IRI). Although the mechanism 
governing vulnerability of the diabetic heart to IRI is still not fully 
understood, alterations in cardiac metabolism have been suggested to 
play an important role in its pathology. At the setting of ischemia, a 
significant reduction of oxygen supply occurred due to the inadequate 
blood supply [14]. During prolonged ischemia, there is an increase in 
anaerobic glycolysis for ATP generation in the myocardium utilized 
for cardiac contraction, in which results in intracellular acidosis and 
inhibition of glycolysis as well as mitochondrial dysfunction [15]. In 
the diabetic heart, the earliest change is altered energy metabolism 
where, the heart switches from glucose utilization to predominantly 
using fatty acids (FA) for energy supply, which subsequently increase 
FA oxidation and triglyceride (TG) accumulation in the heart [16].
When ischemia/reperfusion is imposed in a setting of diabetes, there 
is rapid recovery of FA β-oxidation (circulating FA are augmented as a 
consequence of lipolysis), and glucose oxidation is additionally reduced, 
this contributes to profound uncoupling of glucose metabolism, 
provokes mitochondrial uncoupling which increases reactive oxygen 
species (ROS) generation, aggravates intracellular acidosis, further 
increasing diabetic heart susceptibility to IRI [14] (Figure 1).
The Forkhead box of class O (FoxO) plays a pivotal role in a number 
of cellular processes and are critical regulators of cellular oxidative 
stress response pathways. Abundant evidence now suggests that FoxO 
is important for cardiac metabolic regulation and maintenance of 
cardiac function. This review intends to help understand the role of 
FoxO in regulating the vulnerability of the diabetic heart to IRI and 
its potential role in regulating the responsiveness of the diabetic hearts 
to therapeutic interventions like IPC, IPostC, and APC, in order to 
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Abstract
Diabetes, characterized by hyperglycemia resulting from either insulin deficiency or insulin resistance, is a chronic 
metabolic disorder. Hearts of subjects with diabetes are more sensitive to myocardial ischemia/reperfusion injury 
but the underlying mechanism is largely unclear. Recent evidence suggests that alteration in cardiac metabolism 
is a key contributor to the increased vulnerability of diabetic heart to ischemia/reperfusion injury. The FoxO family 
of forkhead transcription factors including FoxO1, 3 and 4 play important roles in the regulation of many cellular 
and biological processes and are critical regulators of cardiac metabolism and cellular oxidative stress in the heart. 
This brief review focuses on the role of FoxO in regulating cardiac metabolism and its association with myocardial 
ischemia/reperfusion injury, especially in diabetes.
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facilitate the development of effective means of cardioprotection to 
diabetic hearts under the circumstance of ischemia/reperfusion.
Forkhead Box (other) Transcriptional Factor: Its 
Regulation and Biological Function
Forkhead box (Other) transcriptional factors (FoxO) are 
members of the forkhead family of transcriptional regulators, which 
have a DNA-binding forkhead helix domain, a nuclear localization 
sequence, a nuclear export sequence and a C-terminus containing a 
transactivation domain. FoxO proteins (including FoxO1, FoxO3 and 
FoxO4) are expressed in almost every tissue, of which, FoxO1 and 
FoxO3 are expressed in developing and adult heart, participating in a 
wide range of cellular processes including oxidative stress resistance, 
energy metabolism, cell survival and cell death.
FoxO1 and FoxO3 bind to an identical DNA target sequence, 
thus regulating similar target genes. By binding to DNA through 
their forkhead domain, these proteins either inhibit or activate target 
protein gene expression [17]. The fate of FoxO is controlled by three 
major post-translational modifications, including phosphorylation, 
acetylation and ubiquitination [18], which determine their cellular 
compartmentalization, DNA binding, and degradation [19]. Initially 
FoxO proteins are phosphorylated by the protein kinase Akt, the 
downstream target of insulin mediated survival signaling pathway, thus 
insulin is considered as the primary regulator of FoxO [20]. After being 
phosphorylated by insulin, Akt phosphorylates FoxO1 at site Ser256, 
making it prone to further phosphorylation at Ser319 and Thr24 by 
Akt [21]. Following phosphorylation by Akt, FoxO1 binds to 14-3-3, 
which reduces FoxO DNA binding ability and facilitates its nuclear 
exclusion and segregation in the cytoplasm, which subsequently 
undergoes degradation by E3 ubiquitin ligase-mediated ubiquitination 
[18]. In addition to insulin, stress signals like AMPK and JNK are 
also known to phosphorylate FoxO at different sites, which disrupt its 
binding ability to 14-3-3, leading to its nuclear retention [22]. FoxO is 
also acetylated by CBP/p300, which reduces its DNA binding ability 
and transcriptional function [23], whereas deacetylation by Sirtuins 
increase FoxO nuclear retention and transcriptional activity [24].
FoxO plays important roles in many cellular processes. FoxO 
regulates insulin signaling and glucose and lipid metabolism in the 
heart [25,26]. Cardiac specific activation of FoxO1 alone is sufficient to 
adversely alter cardiac metabolism and cause pathological remodeling 
and dysfunction [27]. Deletion of FoxO1 in cardiomyocytes shifted 
their metabolic substrate usage, from FA to glucose, and decreased the 
cardiac lipid content, which reversed high fat diet induced declines in 
cardiac function [27]. Inhibition or gene knockout of FoxO1 reduces 
post-ischemic infarction in the brain [28]. Nuclear FoxO activation 
by Glucocorticoids increase pyruvate dehydrogenase kinase 4 (PDK4) 
expression and activity, thereby suppressing cardiac glucose oxidation 
and further lead to cardiac pathologies by upregulating lactate 
formation and inducing lipotoxicity [29]. Similarly, study in in vivo 
model showed that, administration of intralipid in rats upregluated 
FoxO1 nuclear presence in cardiomyocytes, contributing to cardiac 
insulin resistance and cell death via FoxO1-iNOS-CD36 axis [30]. In 
addition, streptozotocin- and diazoxide- induced hypoinsulinemia 
and hyperglycemia has been shown to increase cardiac nuclear FoxO1 
activation which upregulate iNOS expression, and subsequently 
activates cell death signaling [28]. All these indicate that FoxO1-iNOS 
may serves as the bridge to connect the changes of cardiac metabolism 
and cell death pathway stimulations, especially under pathologic 
conditions like diabetes. Furthermore, these properties of FoxO1 may 
also make it a potential mediator of the increased sensitivity of the 
diabetic heart to IRI.
Cardiac Metabolic Dysfunction may Increase Diabetic 
Heart Vulnerability to IRI
Diabetic heart is more susceptible to IRI [31], but the mechanism 
is unclear. Alterations in cardiac metabolism may exaggerate IRI. In 
the healthy heart, approximately two-thirds of the energy required 
for cardiac contractility derives from fatty acid (FA) oxidation, with 
the remainder from glucose and lactate metabolism. During cardiac 
ischemia, glucose becomes the preferred substrate, as it requires less 
oxygen for oxidation than an equimolar amount of carbon derived 
from FA [32,33]. This is particularly beneficial in the stressed heart 
with limited oxygen supply [16]. However, in diabetes, cardiac glucose 
utilization is depressed, which causes a switch to predominantly 
using FA for energy supply [14]. When diabetic hearts are subjected 
to ischemia, high levels of FA uptake suppress glucose oxidation, 
reduces ATP supply, thereby increasing lactate accumulation and 
electromechanical uncoupling in cardiomyocytes, resulting in cardiac 
acidosis and dysfunction [34,35]. In diabetic heart, high levels of FA 
delivery exceeds the oxidative capacity of the cell, resulting in excessive 
cardiac FA accumulation, elevated oxygen demand, mitochondrial 
uncoupling, reactive oxygen species (ROS) overproduction, and 
mitochondrial dysfunction, which provoke cardiac cell death and 
exacerbate myocardial IRI [36]. Thus, metabolic and the subsequent 
mitochondrial dysfunction may be the fundamental mechanism 
through which diabetic hearts are more susceptible to IRI. Elucidating 
the mechanism governing metabolic alterations and identifying a 
potential central controller that may reverse this metabolic switch in 
diabetes is of importance in preventing IRI in diabetic heart.
FoxO is a recently identified regulator of cardiac metabolism. 
Activation of FoxO1 upgrades cardiac FA uptake and oxidation [27], 
and inhibits glucose utilization, whereas FoxO3 deletion rendered 
mice prone to cardiac hypertrophy [37]. In the heart, both FoxO1 
Figure 1: Cardiac FoxO regulates metabolism. Diabetes or high glucose/high 
lipid increases FoxO nuclear retention which leads to metabolic dysfunction 
with subsequent increase in the production of reactive oxygen species (ROS), 
making the heart prone to ischemia/reperfusion injury. 
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and 3 regulate metabolism [38,39]. This indicates that enhanced FoxO 
activation may serve as an early key trigger of metabolic dysfunction 
that renders diabetic heart more susceptible to IRI.
Changes of Foxo1 in Diabetic Hearts and its Potential 
Impact on Myocardial Vulnerability to IRI
FoxO plays important roles in many cellular processes. FoxO 
regulates insulin signaling and glucose and lipid metabolism in the 
heart [25,26]. Three FoxO isoforms, namely, FoxO1, FoxO3, and 
FoxO4 (with FoxO1 being the dominant member in the adult heart), 
are critical for the maintenance of cardiac functions, including response 
to oxidative stress [20] and regulation of metabolism in the heart [38].
Activated FoxOs upregulate PDK4 that inactivate pyruvate 
dehydrogenase (PDH), a controlling enzyme that favors glucose 
oxidation, and shifts the cell from glucose metabolism toward FA 
utilization [40]. FoxOs also increase mitochondrial CD36 (the 
predominant cardiac FA transporter) and enhance FA uptake [41]. 
To perform these metabolic functions, nuclear presence of FoxO is 
mandatory [42]. In vivo study shows that FoxO1 nuclear presence 
is increased in cardiomyocytes of rats treated with intralipid, which 
upregulates cardiac inducible nitric oxide synthase (iNOS) and 
CD36 expression, contributing to activation of nitrosative stress 
and triglyceride (TG) accumulation in myocardium, which also 
triggers cardiac Protein phosphatase 2A (PP2A) expression, and 
may subsequently contributed to cardiac insulin resistance and cell 
death [30]. In diabetes (streptozotocin- and diazoxide- induced 
hypoinsulinemia and hyperglycemia), FoxO activation (in the presence 
of increased FA supply in diabetes) enhances FA uptake in excess 
of oxidation, upregluating iNOS expression, which subsequently 
nitrosylate GAPDH, leading an increased nitrosative stress in the 
nucleus, and eventually activate Poly [ADP-ribose] polymerase 1 
(PARP-1) mediated cell death signaling [28,30] (Figure 1). Indeed, 
in normal condition, nitric oxide (NO) produced from iNOS may 
enhance defensive response against reperfusion injury at the early stage, 
however, after prolonged reperfusion or hyperglycemic condition (e.g. 
diabetes) that is associated increased in superoxide anion production, 
NO produced from iNOS is significantly increased, which enhances 
peroxynitrite formation, resulting in depression of myocardial 
contractility [43]. This suggests that upregulation of iNOS by FoxO 
under diabetic condition is detrimental to the heart, especially when 
the heart is subjected to ischemia and reperfusion. FoxO is regulated 
by insulin [44] via Akt-dependent phosphorylation at site S253 which 
inactivate FoxO, making it prone to 14-3-3 binding [44] and subsequent 
nuclear exclusion to cytosol, reducing its transcriptional activity [23]. 
In the cytosol, FoxO undergoes ubiquitination and degradation [18]. 
In diabetes, Akt activation is reduced [10] and cardiac 14-3-3 decreased 
[45], increasing FoxO nuclear retention. FoxO is also regulated by 
acetylation, which reduces its activity [46]. Deacetylation of FoxO 
needs silent information regulator1 (Sirt1) [47], leads to activation of 
FoxO [48]. 
Of note, Sirt1 mediated cardioprotection against IRI needs the 
participation of FoxO1, which is essential for Sirt1 to upregulate 
antioxidative manganese superoxide dismutase (Mn-SOD) [49]. 
Moderate increase of cardiac FoxO1 reduced while its cardiac deletion 
exacerbated cardiac IRI in mice [20]. However, these studies were 
performed in non-diabetic conditions, where slight increase in ROS (as 
occurs during ischemia) may activate FoxO1, which in the presence of 
Sirt1 promotes vascular resistance to oxidative stress by transcriptional 
activation of catalase and Mn-SOD that remove ROS [47]. In addition, in 
vitro studies show that Sirt1 increases the ability of FoxO3 to resistance 
to oxidative, while, Sirt1 also inhibits FoxO3 to induce cell death [50]. 
In diabetes, excessive increase in myocardial ROS, not only stimulates 
stress signals [51] which disrupts the binding of 14-3-3 to FoxO [22] 
but most importantly it impairs Akt signaling [10,28]. These changes 
jointly lead to increased myocardial nuclear FoxO (especially FoxO1) 
activation. In type 1 diabetic rats, cardiac Sirt1 initially increased at 
4 weeks, but it was soon significantly decreased with the progression 
of diabetes [52]. Thus, an increase of cardiac FoxO especially FoxO1 
activation, in the presence of decreased Sirt1, in the late phase of 
diabetes diminishes FoxO1 function in enhancing antioxidant enzymes 
while promotes its metabolic regulatory function. Our preliminary 
study performed in isolated cardiomyocytes showed that incubating 
cardiomyocytes with high glucose and high lipid increased nuclear 
presence of FoxO1 with concomitant increase in cardiomyocytes CD36 
over-expression which is associated with increased cellular injury when 
the cells were subjected to hypoxic reoxygenation (Figure 2). Taken 
together, studies by other and us provide evidence to suggest that under 
diabetic condition, increase in cardiac FoxO under the stimulation 
of high glucose and high lipid, may play a central role in rendering 
diabetic heart more sensitive to IRI (Figures 1 and 2), although further 
in depth studies are needed to confirm this hypothesis.
Myocardial Conditioning: FoxO as Convergence of 
Cardioprotective Pathways
Cardioprotective effects of IPC, IPostC and APC (myocardial 
conditioning) have been extensively studied [6,53,54]. IPC, IPostC and 
APC confer their cardioprotection via activation of the Reperfusion-
Injury-Salvage-Kinase (RISK) pathway (phosphatidylinositol3-kinase 
(PI3K)-Akt signaling [55]) and the Survivor-Activating-Factor-
Enhancement (SAFE) pathway (Jak/STAT3 signaling) [56] which can 
be activated independent of the RISK pathway [57,58]. However, these 
pathways are impaired in the diabetic myocardium, making it difficult 
to pre- or post-condition the diabetic hearts [58]. The mechanism 
whereby impairment in STAT3 and/or Akt activation compromises 
myocardial conditioning, cardioprotection in diabetes is unknown.
Akt phosphorylates/inactivates FoxO and confers cellular 
protection [59]. Inactivation of FoxO1 also needs STAT3, and FoxO1 
was persistently activated in STAT-3 deficient mice which led to the 
loss of cardioprotection induced by sphingosine-1-phosphate (this 
confers cardioprotection via both the RISK and SAFE pathways) 
[60]. This suggests that FoxO is the downstream target of both Akt 
Figure 2: Isolated cardiomyocytes were exposed to normal glucose (glucose 
5.5 mM, Control) or high glucose (HG) and high lipid (HL) (HG/HL, 25 mM 
Glucose and 1 mM palmitate). HG/HL increased Cardiomyocytes nuclear 
presence of FoxO1 (A) and reduced cytosolic FoxO1 (data not shown) and 
increased CD36 protein expression (B) after 4 hours of treatment. Cell injury 
assessed as increased release of LDH was more severe in cardiomyocytes 
exposed to HG/HL than in control when cells were subjected to 45 min of 
hypoxia followed by 2 hours of reoxygenation (C). Data are mean ± SD, n=6/
group. *P< 0.05, ** P<0.01. 
Citation: Li H, Irwin MG, Tao M, Li Y, Zhang L, et al. (2013) Role of Forkhead Transcription Factors in Myocardial Ischemic Reperfusion Injury in 
Diabetes. J Diabetes Metab 4: 247. doi:10.4172/2155-6156.1000247
Page 4 of 5
Volume 4 • Issue 3 • 1000247
J Diabetes Metab
ISSN:2155-6156 JDM, an open access journal
and STAT-3 and serves as critical convergence of the RISK and SAFE 
pathways. Thus, inhibition of FoxO may not only enhance diabetic 
heart tolerance to IRI but also restore diabetic heart responsiveness to 
myocardial conditioning.
Conclusions
Myocardial infarction is the major cause of death in patients 
with diabetes and there is repaid prevalence of diabetes worldwide. 
To date, effective therapeutic strategies to protect the diabetic heart 
from IRI remain limited. FoxO is a major transcription factors that 
regulate cardiac metabolism, however, its role in the heart during 
pathological conditions like diabetes has not been fully elucidated. 
Gaining more insight into the mechanism(s) by which cardiac FoxO 
are regulated may assist in developing new therapeutic strategies to 
improve cardiac function during diabetes and to restore effectiveness 
of cardioprotective interventions (ischemic preconditioning, IPC or 
ischemic postconditiong, IPostC) in the setting of diabetes.
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